Ovid Therapeutics
OVID
Ovid Therapeutics (OVID) earnings history
Most recent quarter
- Fiscal period
- Q2 2025
- Period end
- Jun 30, 2025
- EPS actual
- −$0.06
- EPS estimate
- −$0.16
- EPS surprise
- +62.00%
- Revenue surprise
- +6289.11%
- Revenue
- $6.3M
- Revenue estimate
- $98,167.00
- Reported
- Aug 13, 2025
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2025 | Aug 13, 2025 | −$0.16 | −$0.06 | +62.00% | $6.3M | SEC |
| Q1 2025 | May 13, 2025 | −$0.14 | −$0.14 | −1.82% | $130,000.00 | SEC |
| Q4 2024 | Mar 11, 2025 | −$0.17 | −$0.13 | +22.94% | $76,000.00 | SEC |
| Q3 2024 | Nov 12, 2024 | −$0.21 | −$0.20 | +3.15% | $173,000.00 | SEC |
| Q2 2024 | Aug 13, 2024 | −$0.22 | $0.12 | +153.60% | $169,000.00 | SEC |
| Q1 2024 | May 14, 2024 | −$0.22 | −$0.17 | +23.94% | $148,000.00 | SEC |
| Q4 2023 | Mar 8, 2024 | −$0.05 | −$0.22 | −335.64% | $141,562.00 | SEC |
| Q3 2023 | Nov 3, 2023 | −$0.19 | −$0.16 | +13.70% | $108,972.00 | SEC |
| Q2 2023 | Aug 4, 2023 | −$0.20 | −$0.18 | +11.89% | $75,000.00 | SEC |
| Q1 2023 | May 5, 2023 | −$0.17 | −$0.19 | −10.98% | $66,160.00 | SEC |
| Q4 2022 | Mar 13, 2023 | −$0.17 | −$0.16 | +6.92% | $46,280.00 | SEC |
| Q3 2022 | Nov 8, 2022 | −$0.21 | −$0.17 | +20.63% | $11,102.00 | SEC |
| Q2 2022 | Aug 9, 2022 | −$0.25 | −$0.21 | +15.59% | $0.00 | SEC |
| Q1 2022 | May 10, 2022 | −$0.21 | −$0.23 | −11.00% | $1.4M | SEC |
| Q4 2021 | Mar 15, 2022 | −$0.16 | −$0.38 | −135.88% | $0.00 | SEC |
| Q3 2021 | Nov 10, 2021 | −$0.19 | −$0.17 | +10.05% | $0.00 | SEC |
| Q2 2021 | Aug 16, 2021 | −$0.16 | −$0.23 | −40.24% | $0.00 | SEC |
| Q1 2021 | May 13, 2021 | $1.45 | $2.53 | +74.66% | $208.4M | SEC |
| Q4 2020 | Mar 15, 2021 | −$0.31 | −$0.34 | −11.26% | $5.7M | SEC |
| Q3 2020 | Nov 12, 2020 | −$0.35 | −$0.28 | +20.09% | $6.9M | SEC |
Quarterly revenue
Frequently asked questions
When did Ovid Therapeutics (OVID) last report earnings?
Ovid Therapeutics last reported on Aug 13, 2025, covering fiscal Q2 2025.
Did OVID beat earnings estimates?
Yes. Ovid Therapeutics reported EPS of −$0.06 for Q2 2025 against a −$0.16 estimate — a 62.00% beat.
How much revenue did OVID report last quarter?
Ovid Therapeutics reported $6.3M in revenue for Q2 2025, against a consensus estimate of $98,167.00.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.